OVERVIEW

Switching and Monitoring Your Patients with RRMS is organized by CME Outfitters, LLC.

Dates:
Premiere Date: Tuesday, September 15, 2020
Credit Expiration Date: Wednesday, September 15, 2021

Accreditation:
CME Credit (Physicians):
CME Outfitters, LLC, designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to PAs:
PAs may claim a maximum of .25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .25 contact hours (0.025 CEUs)

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

This activity offers CE credit for:
• Physicians (CME)
• Pharmacists (ACPE)
• ABIM (MOC)
• Other

Statement of Need:
Predictors of poor prognosis in multiple sclerosis (MS) can include demographic and environmental factors, clinical factors, MRI observations, and biomarkers. Early initiation of appropriate therapy is key when personalizing treatment for relapsing-remitting multiple sclerosis (RRMS), as is having a plan to determine sub-optimal responders, approaches to switching or escalating therapy, and consideration of more aggressive therapies for patients with silent advanced disease or early signs of poor prognosis.

In this CMEOCast podcast, expert faculty discuss treatment initiation options, particularly high efficacy treatments versus escalation, as well as when switching therapies might be necessary and how to take patient- and medication-related issues into consideration.

Learning Objectives:
At the end of this CE activity, participants should be able to:
• Develop individualized treatment plans based on clinical characteristics of patients with RRMS.
• Integrate strategies for delivering patient-centered care in patients with RRMS.
• Assess patients for disease activity and switch when response is suboptimal.

The following learning objectives pertain only to those requesting CNE or CPE credit:
• Evaluate the latest clinical data on the safety and efficacy of current and emerging therapies for RRMS.
• Describe an individualized treatment plan based on clinical characteristics of patients with RRMS.
• Summarize strategies for delivering patient-centered care in patients with RRMS.